Adage Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.8M Buy
2,289,203
+40,000
+2% +$520K 0.05% 361
2026
Q2
$29.9M Buy
2,249,203
+644,047
+40% +$6.28M 0.04% 392
2026
Q1
$14.9M Buy
1,605,156
+370,000
+30% +$3.22M 0.02% 578
2025
Q4
$9.26M Buy
1,235,156
+1,060,156
+606% +$10.8M 0.01% 681
2025
Q3
$1.52M Buy
+175,000
New +$1.05M ﹤0.01% 822

Other funds holding FDMT

Adage Capital Partners's FDMT Position: Q3 2026 in Review

Adage Capital Partners increased its 4D Molecular Therapeutics (FDMT) stake by 1.8% in Q3 2026, buying an estimated $520K and bringing the position to 2,289,203 shares worth $32.8M. The position accounts for 0.05% of the portfolio, ranked #361.

Adage Capital Partners first reported a position in FDMT in Q3 2025 and has held it in 5 quarters since. 161 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Adage Capital Partners held 2,289,203 shares of 4D Molecular Therapeutics worth $32.8M as of Q3 2026.
  • Adage Capital Partners bought 40,000 4D Molecular Therapeutics shares in Q3 2026, an estimated $520K.
  • 4D Molecular Therapeutics made up 0.05% of Adage Capital Partners's portfolio in Q3 2026, its #361 holding.
  • Adage Capital Partners first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 161 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.